SAN DIEGO, May 1, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its continued support of increasing awareness regarding the prevalence, impact and importance of screening for tardive dyskinesia (TD), during Tardive Dyskinesia Awareness Week, May 1-7. TD is an involuntary movement disorder associated with prolonged use of certain mental health medicines (antipsychotics) that can be used to treat bipolar disorder, depression, schizophrenia and schizoaffective disorder.1,3,4
Read more at prnewswire.comProvided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.